Age-related macular degeneration (AMD): Your questions answered

Written by: Mrs Samantha Mann
Published:
Edited by: Carlota Pano

Age-related macular degeneration (AMD) is a common eye disease among people over the age of 50 that affects central vision, causing distorted, blurred or reduced vision.

 

Here, Mrs Samantha Mann, renowned consultant ophthalmologist, provides an expert insight into AMD. The London-based specialist discusses risk factors, diagnosis, and treatment, among other important points.

 

 

How is AMD evaluated and diagnosed?

 

AMD is evaluated based on the patient’s symptoms. If the patient complains of distortion of vision in one eye or difficulty with reading, an eye examination and then an OCT scan at the back of the eye are normally carried out. To be able to diagnose AMD, there needs to be evidence of disruption of the outer layers of the retina (the central area at the back of the eye that’s used for reading).

 

AMD is typically divided into wet and dry forms of macular degeneration. It’s especially important to diagnose the wet form, which results in abnormal blood vessels growing into the retina and causing leakage and bleeding, because wet AMD can be treated with injection therapy if it’s detected early enough. Unfortunately, there’s currently no effective treatment for the dry type of macular degeneration.

 

What factors can predispose the development of AMD?

 

Patients who have a family history of AMD and patients who smoke are at increased risk.

 

In addition, many patients develop drusen deposits at the back of their eye, which are small lumps of a waste product that builds up just underneath the retina. These deposits can predispose the eye to developing wet AMD, which then causes increased distortion of vision.

 

Patients who have drusen deposits are often given an Amsler Grid to monitor their vision. If they notice any change in their vision while checking the Amsler Grid, patients should see their ophthalmologist promptly.

 

If left untreated, how can AMD affect vision?

 

If AMD is left untreated, it can result in permanent scarring at the back of the eye and the actual loss of central vision. AMD rarely affects side vision, but it can impact reading and the ability to recognise faces.

 

What types of treatments are available for AMD?

 

Anti-VEGF injections are generally used. This is the best treatment for wet AMD, as it can help prevent the abnormal blood vessels from bleeding and leaking at the back of the eye. Currently, ranibizumab, aflibercept, or the newer brolucizumab injection are used, because these are licensed options approved by the National Institute for Health and Care Excellence for use into the back of the eye.

 

While anti-VEGF injections might sound scary, the injections are actually quite quick and simple to deliver into the back of the eye, with minimal discomfort for the patient. They typically cause a bit of grittiness for about 24 hours, but most patients are able to resume their normal routine the following day.

 

The downside to anti-VEGF injections is that they have to be given quite regularly. Initially, this is monthly. After, treatment is carried on for at least a few years to achieve the best outcome.

 

How many anti-VEGF injections can a patient with AMD receive?

 

Many patients require multiple anti-VEGF injections for several years. Initially, the injections are given monthly. Over time, the frequency is usually reduced to two monthly or three monthly as the fluid and leakage decrease.

 

The risk of severe infection or any problems following anti-VEGF injections is generally very low.

 

Can anti-VEGF injections be used in combination with other treatments, such as steroid injections?

 

Currently, the only drugs licensed to be used for the treatment of wet AMD are anti-VEGF injections such as ranibizumab, aflibercept and brolucizumab.

 

Steroid injections are only used for other conditions, such as diabetic maculopathy or retinal vein occlusion, when anti-VEGF injections have proven to be ineffective.

 

 

Mrs Samantha Mann is a leading consultant ophthalmologist with over 25 years’ experience who specialises in the treatment of medical retina conditions such as AMD.

 

If you require expert diagnosis and treatment for AMD, don’t hesitate to book an appointment with Mrs Mann via her Top Doctors profile today.

By Mrs Samantha Mann
Ophthalmology

Mrs Samantha Mann is a leading consultant ophthalmologist specialising in medical retina who treats patients from in and around London. With over 25 years of experience, she is highly specialised in the treatment of conditions affecting the retina such as diabetic retinopathy, age-related macular degeneration, retinal vein occlusion, and central serous retinopathy. Additionally, Mrs Mann is an expert in intravitreal injections of both anti-VEGF agents and steroid implants and retinal laser treatments.   
  
In 1996, Mrs Mann qualified as a doctor from St Bartholomew’s hospital in London with distinction and first-class honours in her intercalated BSc. She then gained general medical experience as she trained in various London hospitals before pursuing a career in ophthalmology. Part of her ophthalmic rotation was spent at St Thomas’ hospital after which she spent five years as a specialist registrar and fellow at Moorfield’s Eye Hospital, during which she completed and was awarded an MD for her research into age-related macular degeneration. She was also awarded the Harcourt Medal by the Royal College of Ophthalmologists in 2001 for her performance in her final examinations. 
  
Mrs Mann is currently a consultant ophthalmologist at her NHS base, Guy’s and St Thomas’ Hospital, where she has practised since 2009. Here, she is one of three medical retinal consultants. Privately, she sees patients at the renowned London Medical Clinic. Furthermore, she is the clinical lead for South East London’s Diabetic Eye Screening Programme, which is responsible for over 120,000 patients with diabetes. She also led the production of a video entitled ‘Danny’s Story’ emphasising the importance of eye screening for patients with diabetes. 
  
In addition to her clinical work, Mrs Mann maintains a keen research interest, particularly in age-related macular disease and diabetic eye screening. She has authored numerous peer-reviewed papers. Currently, she is the principal investigator of Thomas’ Hospital’s PINNACLE study, having previously held the role in two vein occlusion treatment trials. Over the last 10 years she has had an active role in teaching and running courses for trainees and other health professionals on diabetic retinopathy, laser for diabetes, and on the progression of retinopathy in pregnancy.  She is also a Fellow of the Royal College of Ophthalmologists.   

View Profile

Overall assessment of their patients


  • Related procedures
  • Microdermoabrasion
    Microneedling
    Dark circles
    Mesotherapy
    Facelift
    Neck lift
    Botulinum toxin (Botox™)
    Dermal fillers
    Peeling
    Facial paralysis
    This website uses our own and third-party Cookies to compile information with the aim of improving our services, to show you advertising related to your preferences as well analysing your browsing habits. You can change your settings HERE.